Oct 05, 2022

Researchers’ mission was to analyze the effect of an Enhanced Recovery After Surgery (ERAS) procedure on the rate of opioid prescription renewals and unplanned patient-provider contacts in the first...

Oct 05, 2022

The purpose of this research was to evaluate whether or not women who underwent superficial or deep inguinal lymph node dissections for suspected early-stage vulvar cancer had a higher rate of groin r...

Oct 05, 2022

Growing evidence shows a role for other genes that may disclose new clinical care options for hereditary uterine cancer (UC), which has historically been linked to pathogenic/likely pathogenic germlin...

Oct 04, 2022

High-grade serous ovarian cancer (HGSOC) is the most frequent subtype of ovarian cancer and is associated with high mortality rates. The surgical outcome is one of the most important prognostic variab...

Oct 04, 2022

Studies have shown that survivors of cervical cancer often have trouble sleeping. But there isn't a lot of data on hypnotics' effectiveness. Researchers looked for indicators of long-term hypnotic usa...

Oct 04, 2022

When it comes to uterine leiomyosarcoma (uLMS), the best adjuvant treatment has yet to be determined. Researchers assessed the frequency with which stage II and III uLMS had adjuvant chemotherapy and ...

Oct 04, 2022

Since the bulk of human epididymis protein 4 (HE4) studies was conducted in oncology facilities, it is uncertain how useful serum HE4 is in guiding referral decisions in patients with an ovarian tumor...

Oct 04, 2022

For the treatment of obvious early-stage endometrial cancer (EC), sentinel lymph node mapping (SNM) has become increasingly popular. Here, researchers examined how well 3 distinct methods of nodal ass...

Oct 04, 2022

Patients with epithelial ovarian cancer (EOC) are encouraged to have adjuvant chemotherapy administered no later than 42 days after surgery. This research aimed to determine whether or not postponing ...

Oct 04, 2022

Patients with recurrent ovarian cancer can evaluate the efficacy and safety of palliative chemotherapy by using the Measure of Ovarian Symptoms and Treatment (MOST) concerns; a validated patient-repor...

Oct 04, 2022

In the phase 2 multi-cohort KEYNOTE-158 study, pembrolizumab showed an objective response rate that was clinically significant in patients with advanced MSI-H/dMMR endometrial cancer who had had prior...

Oct 04, 2022

Patients with high-risk histology endometrial cancer (EC; grade 3 endometrioid adenocarcinoma, papillary serous carcinoma [PS], clear cell carcinoma [CC], and carcinosarcoma) were compared between min...

Oct 04, 2022

To examine the safety and efficacy of niraparib+bevacizumab as first-line maintenance therapy for patients with newly diagnosed advanced ovarian cancer. This multicenter, phase II, single-arm, open-la...

Oct 04, 2022

Treatment options for advanced vulvar cancer are limited. Researchers evaluated pembrolizumab monotherapy in patients with advanced vulvar squamous cell carcinoma (SCC) enrolled in phase 2 multicohort...

Oct 03, 2022

A multidisciplinary agreement was used to determine whether or not patients diagnosed with advanced epithelial ovarian cancer (AEOC) between October 2018 and October 2020 should receive primary chemot...

Oct 03, 2022

The goal of this study was to compare the efficacy of an ultrasound-guided block (US-Tap) and laparoscopically-guided transversus abdominis plane block (Lap-Tap) with liposomal bupivacaine in the trea...

Oct 03, 2022

For patients with BRCA1/BRCA2-mutated (BRCAm), platinum-sensitive relapsed ovarian cancer (PSROC), and 2 prior lines of platinum-based chemotherapy, the SOLO3 phase III trial found that treatment with...

Oct 03, 2022

As shown by the Laparoscopic Approach to Cervical Cancer (LACC) trial, early-stage cervical carcinoma patients who undergo a minimally invasive (MIS) radical hysterectomy have poorer oncologic outcome...

Oct 03, 2022

If a patient with advanced epithelial ovarian cancer (EOC) lives without disease progression for 10 years after diagnosis, they are considered to be cured. Researchers describe the percentage of patie...

Oct 03, 2022

Researchers claim that they conducted a Phase I trial to assess the efficacy and safety of paclitaxel, sapanisertib, and serabelisib. This was an open-label cohort trial comparing sapanisertib (TAK-22...